PSA and survival data set

This data set has been originally published in:

Desmée, S, Mentré, F, Veyrat-Follet, C, Sébastien, B, Guedj, J (2017). Using the SAEM algorithm for mechanistic joint models characterizing the relationship between nonlinear PSA kinetics and survival in prostate cancer patients. Biometrics, 73, 1:305-312.

It contains PSA kinetics and survival data for 400 men with metastatic Castration-Resistant Prostate Cancer (mCRPC) treated with docetaxel and prednisone, the first-line reference chemotherapy, which constituted the control arm of a phase 3 clinical trial. In this context of advanced disease, the incidence of death is high and the PSA kinetics is closely monitored after treatment initiation to rapidly detect a breakthrough in PSA and propose rescue strategies. In more details:

  • PSA kinetics: 6627 PSA measurements were collected, among which roughly 20% were pretreatment, 60% on treatment, and 20%posttreatment. 2.5% are below the limit of quantification (LoQ),set at 0.1−1.
  • survival: 286 patients deceased (71.5%), leading to a median survival of 656 days.

PSA measurements are displayed on the figure below. Since the data density is too high to see clearly, the next figure is a selection of six individuals, that allows to identify the shape of PSA measurements followed by most individuals: a decrease of PSA concentration after the treatment initiation at time zero, followed by an increase some time later due to resistance.

The following figure shows the Kaplan-Meier curves for the survival data split in two groups by the median time of end of treatment

Below is an extract of the data set file:

The columns are: